Indaptus Therapeutics (NASDAQ:INDP) Shares Down 3.1% – Should You Sell?

Indaptus Therapeutics, Inc. (NASDAQ:INDP) shares dropped 3.1% during mid-day trading on Tuesday . The stock traded as low as $12.01 and last traded at $12.19. Approximately 5,128 shares traded hands during trading, a decline of 92% from the average daily volume of 63,737 shares. The stock had previously closed at $12.58.

Indaptus Therapeutics Trading Down 3.1%

The firm has a market cap of $6.95 million, a P/E ratio of -0.29 and a beta of 1.35. The company’s 50 day simple moving average is $10.73 and its 200-day simple moving average is $16.98.

Indaptus Therapeutics (NASDAQ:INDP) last posted its earnings results on Wednesday, May 14th. The company reported ($8.96) earnings per share (EPS) for the quarter, beating the consensus estimate of ($11.48) by $2.52. On average, sell-side analysts anticipate that Indaptus Therapeutics, Inc. will post -1.79 earnings per share for the current year.

About Indaptus Therapeutics

Indaptus Therapeutics, Inc, a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial.